Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-09-20
2005-09-20
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S565000, C514S668000, C514S718000, C514S088000, C514S908000, C514S929000
Reexamination Certificate
active
06946484
ABSTRACT:
Methods and formulations for inhibiting and preventing a malignant cell phenotype by administering to cells a low dose of a nitric oxide mimetic are provided.
REFERENCES:
patent: 5434256 (1995-07-01), Khokhar et al.
patent: 5849790 (1998-12-01), Palmer et al.
patent: 6057367 (2000-05-01), Stamler et al.
patent: 6103275 (2000-08-01), Seitz et al.
patent: 6153186 (2000-11-01), Stamler et al.
patent: 6171620 (2001-01-01), Piver et al.
patent: 6180824 (2001-01-01), Stamler et al.
patent: 6203789 (2001-03-01), Stamler et al.
patent: 6235782 (2001-05-01), Pamukcu et al.
patent: 6270779 (2001-08-01), Fitzhugh et al.
patent: 2001/0038832 (2001-11-01), Bonavida
patent: 2002/0010146 (2002-01-01), Garvey et al.
patent: 2003/0092637 (2003-05-01), Magnusson et al.
patent: 2003/0215528 (2003-11-01), Graham et al.
patent: WO 96/30336 (1996-10-01), None
patent: 98/13358 (1998-04-01), None
patent: WO 99/03462 (1999-01-01), None
patent: 99/33823 (1999-07-01), None
patent: 99/57306 (1999-11-01), None
patent: 00/51597 (2000-09-01), None
patent: 01/54771 A2 (2001-08-01), None
patent: 01/70199 (2001-09-01), None
Ushmorov, A. et al., “Nitric oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and Cytochrome C release,” Blood, vol. 93, No. 7, pp. 2342-2352.
Derwent abstract, accession No. 1998-313779; abstracting DE 19732323 (1998).
Chemical Abstracts 129:36441 (1998).
International Search Report for PCT/CA 01/00566 filed Apr. 26, 2001.
Sumitani et al., Cytotoxic Effect of Sodium Nitroprusside on Cancer Cells: Involvement of Apoptosis and Suppression of C-MYC and C-MYB Proto-Oncogene Expression, Anticancer Research 17:865-872 (1997), XP-001064190.
Umansky et al., Nitric Oxide-Mediated Apoptosis in Human Breast Cancer Cells Requires Changes in Mitochondrial Functions and is Independent of CD95 (APO-1/Fas), International Journal of Oncology 16:109-117 (2000), XP-001064253.
Umansky et al., Activated Endothelial Cells Induce Apoptosis in Lymphoma Cells: Role of Nitric Oxide, International Journal of Oncology 10: 465-471 (1997) XP-001064191.
Dookeran et al., Mechanisms of Antitumor Activity for Sustained-Release Nitric-Oxide Donor, Nitroprusside in Ethiodol, #1782, Cook County Hospital, Chicago, IL, XP-001064169 (date unavailable).
Eley, K.W., et al., “The Effects of Pentoxifylline on the Survival of Human Glioma Cells with Continuous and Intermittent Stereotactic Radiosurgery Irradiation”; Int. J. Radiation Oncology. Biol. Phys. (2002) vol. 54, No. 2, pp 542-550.
Kim, et al., “Type 4 Cyclic Adenosine Monophosphate Phosphodiesterase as a Therapeutic Target in Chronic Lymphocytic Leukemia”, Blood, (Oct. 1, 1998), vol. 92, No. 7, pp. 2484-2494.
YP, et al., “Topical Applications of Caffeine or (−)-Epigallocatechin Gallate (EGCG) Inhibit Carcinogenesis and Selectively Increase Apoptosis in UVB-Induced Skin Tumors in Mice”, Proc. Nat'l Acad. Sci USA (Sep. 27, 2002) (19): 12455-12460, (Abstract only).
Carducci, et al., “Effect of Endothelin-A Receptor Blockage with Atrasentan on Tumor Progression in Men with Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial”, Jour. of Clinical Oncology, (Feb. 15, 2003), vol. 21, No. 4, pp. 679-689.
Marshall, et al., “Nitrosative Stress-Induced Apoptosis Through Inhibition of NF-KB*”, Jour. of Biological Chem., (Sep. 13, 2002), vol. 277, No. 37, pp. 34223-34228.
Chen, et al., “Identification of the Enzymatic Mechianism of Nitroglycerin Bioactivation”, PNAS, (Jun. 11, 2002), vol. 99, No. 12, pp. 8306-8311.
Sun, et al., “Cysteine-3635 is Responsible for Skeletal Muscle Ryanodine Receptor Modulation by NO”, PNAS, (Sep. 25, 2001), vol. 98, No. 20, pp. 11158-11162.
Mannick, et al., “FAS-Induced Caspase Denitrosylation”, Science, (Apr. 23, 1999), vol. 284, pp. 651-654.
Marshall, et al., “Exhaled Nitric Oxide (NO), NO Synthase Activity, and Regulation of Nuclear Factor (NF)-KB”, Am. J. Respir. Cell Mol. Biol., (1999), vol. 21, pp. 296-297.
Stix, Gary, “Saying Yes to NO”, Scientific American, (Nov. 2001), pp. 34.
Chang-Ouk Jun, et al., High-does(sp) nitric oxide induces apoptosis in HL-60 human myeloid leukemia cells; Experimental and Molecular Medicine; Jun. 1996; vol. 28, No. 2, 101-108.
Adams Michael A.
Graham Charles H.
Heaton Jeremy P. W.
Postovit Lynne-Marie
Cellegy Pharmaceuticals Inc.
Pak John
LandOfFree
Formulations and methods of using nitric oxide mimetics... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations and methods of using nitric oxide mimetics..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations and methods of using nitric oxide mimetics... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3424074